These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 26220768

  • 1. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
    Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.
    Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
    [Abstract] [Full Text] [Related]

  • 2. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
    Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin HG.
    Fertil Steril; 2010 Jul; 94(2):666-72. PubMed ID: 19368913
    [Abstract] [Full Text] [Related]

  • 3. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
    de Mendonça-Louzeiro MR, Annichino-Bizzacchi JM, Benetti-Pinto CL.
    Fertil Steril; 2015 Aug; 104(2):467-73. PubMed ID: 26051101
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Cağlayan O, Saygili F, Yilmaz C.
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
    [Abstract] [Full Text] [Related]

  • 6. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
    Karakurt F, Gumus II, Bavbek N, Kargili A, Koca C, Selcoki Y, Ozbek M, Kosar A, Akcay A.
    Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
    [Abstract] [Full Text] [Related]

  • 7. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Altinkaya SÖ, Nergiz S, Küçük M, Yüksel H.
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():168-72. PubMed ID: 24642195
    [Abstract] [Full Text] [Related]

  • 8. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
    Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
    [Abstract] [Full Text] [Related]

  • 9. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Yilmaz SA, Kerimoglu OS, Pekin AT, Incesu F, Dogan NU, Celik C, Unlu A.
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
    [Abstract] [Full Text] [Related]

  • 10. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
    Godtfredsen ACM, Sidelmann JJ, Gram JB, Andersen M, Glintborg D.
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
    [Abstract] [Full Text] [Related]

  • 11. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
    Taskin MI, Bulbul E, Adali E, Hismiogulları AA, Inceboz U.
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
    [Abstract] [Full Text] [Related]

  • 12. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 13. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.
    J Clin Endocrinol Metab; 2002 Feb; 87(2):660-5. PubMed ID: 11836301
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 15. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.
    Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3871-5. PubMed ID: 12161525
    [Abstract] [Full Text] [Related]

  • 16. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 17. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 18. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
    Antovic JP, Rafik Hamad R, Antovic A, Blombäck M, Bremme K.
    Thromb Haemost; 2002 Oct; 88(4):644-7. PubMed ID: 12362237
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-6 levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
    Küçük M, Altınkaya SÖ, Nergiz S, Sezer SD, Yüksel H, Bağlı İ, Yıldız G.
    Gynecol Endocrinol; 2014 Jun; 30(6):423-7. PubMed ID: 24628003
    [Abstract] [Full Text] [Related]

  • 20. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F.
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.